|Security||WBT / Welbilt, Inc. (563568104)|
|President, CEO, Director||Muhlhauser Hubertus M|
|Industry||Refrigeration And Service Industry Machinery|
|Institutional Shares||5,774,735 - 4.13%|
|Common Shares Outstanding||139,927,575 shares (as of 2018-03-31)|
|Institutional Value||$ 111,626,000 USD|
MFS / Manitowoc Foodservice, Inc.|
Institutional Stock Ownership and Shareholders()
Welbilt, Inc. (NYSE:WBT) has 8 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5,774,735 shares.
Largest shareholders include
BlackRock Institutional Trust Company, N.A., BlackRock Fund Advisors, Keeley Asset Management Corp, BlackRock Group LTD, BlackRock Advisors LLC, BlackRock Investment Management, LLC, Group One Trading, L.p., and MetLife Securities, Inc.
Welbilt, Inc. (NYSE:WBT) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/wbt"><img src="https://images.fintel.io/us-wbt-so.png" alt="WBT / Welbilt, Inc. Institutional Ownership"><a>
|BlackRock Investment Management, LLC||59,750||70,025||17.20||969||1,354||39.73|
|MetLife Securities, Inc||4,629||4,495||-2.89||75||87||16.00|
|GROUP ONE TRADING, L.P.||Put||5,200||101|
|BlackRock Fund Advisors||1,305,110||1,395,009||6.89||21,169||26,966||27.38|
|BlackRock Institutional Trust Company, N.A.||3,337,047||3,320,282||-0.50||54,127||64,181||18.57|
|CT Financial Advisors LLC||895||0||-100.00||17,300||0||-100.00|
|BlackRock Group LTD||121,618||97,493||-19.84||1,973||1,884||-4.51|
|KEELEY ASSET MANAGEMENT CORP||811,110||15,679|
|WILLIAM HARRIS INVESTORS INC||257,294||0||-100.00||4,173||0||-100.00|
|BlackRock Advisors LLC||72,661||76,321||5.04||1,179||1,475||25.11|
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
Nordson Corporation (NDSN - Free Report) recently fortified its sealant equipment portfolio with the launch of an automated cartridge dispensing system. The cartridge is an advanced addition to the company’s aerospace assembly and manufacturing solutions product line. Share price of the company remained nearly flat at $130.98, post the product launch news broadcast on Jul 11. Nordson’s latest cartridge dispenser is a premium JetStream robot-mounted product, suitable for application of certain pre-mixed sealant materials in various types of assembly operations, like panel, wing spar, or aircraft door or fuselage sealing. (1-0)
Graco Inc. (GGG - Free Report) recently reinforced its innovation platform with the launch of the Pulse Fluid Management system for vehicle service. The latest wireless system, which includes the company’s popular fluid-management technology, will provide futuristic service operations. These processes will drive profitability and simplify decisions through appropriate control, analytics and insight. (2-0)
Therma-Tru Corp — a leading entry door brand of Fortune Brands Home & Security, Inc. (FBHS - Free Report) — recently teamed up with Renoworks Software Inc. to integrate its Design Your Door tool with the Renoworks home visualization platform. With this integration, homeowners will be able to view the latest library of Therma-Tru doors in their homes with participating Renoworks dealers. (1-0)
The U.S. manufacturing sector continues to gather steam despite sustained uncertainty over the White House international trade policy. In June, the Institute for Supply Management’s (ISM) manufacturing gauge logged its best gain in the last four months. Monday’s ISM report mirrored perked up factory activity in the world’s strongest economy, raising hopes of sturdier GDP growth in the second quarter and additional Fed rate hikes in the back half of the year. (5-0)
Tetra Tech, Inc. (TTEK - Free Report) recently announced that the company has secured a $60-million multiple-award contract from the U.S. Army Corps of Engineers, Portland District. Per the five-year contract, Tetra Tech will provide engineering and design services throughout the Pacific Northwest. (1-0)
as of ET